Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029442 · ClinicalTrials.gov registry record · Phase 4
The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
A Phase 4 study, sponsored by James J. Peters Veterans Affairs Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03029442: Clinical Trial Phase 4 study, sponsored by James J. Peters Veterans Affairs Medical Center.
NCT03029442 is a Phase 4 study that was terminated before completion, run by James J. Peters Veterans Affairs Medical Center. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03029442, a Phase 4 study, was terminated before completion, sponsored by James J. Peters Veterans Affairs Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the usefulness of a drug, denosumab, to prevent the loss of bone in participants legs due to SCI. This drug is FDA approved to treat osteoporosis in women after menopause who have an increased risk for fractures, to treat women receiving certain treatments for breast cancer who have an increased risk of fractures, and to treat bone loss in men receiving certain treatments for prostate cancer who have increased risk for fractures. This drug is considered experimental for the purpose of this study. Study participation will last for approximately 12 months (6 study visits total), visits will range from1-4.5 hours depending on the number of tests that need to be completed. The study is a double-blinded placebo trail in which the participant will be randomly assigned to on of two groups, Denosumab injections or placebo - inactive salt solution injections.
Primary Outcome
Efficacy of denosumab to prevent aBMD loss at the distal femur and proximal tibia
Interventions
- DRUG Denosumab (Prolia)
- OTHER Placebo (normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2022-10-06 |
| Phase | Phase 4 |
Why NCT03029442 stopped before completion
NCT03029442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Denosumab (Prolia) is the first listed.
NCT03029442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03029442 about?
NCT03029442 is a clinical study titled "The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury". The purpose of this study is to determine the usefulness of a drug, denosumab, to prevent the loss of bone in participants legs due to SCI. This drug is FDA approved to treat osteoporosis in women after menopause who have an increased risk for fractures, to treat women receiving certain treatments f...
What is the current status of trial NCT03029442?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2017-04-01. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT03029442?
The interventions under investigation include: Denosumab (Prolia) (DRUG), Placebo (normal saline) (OTHER).
Who is sponsoring clinical trial NCT03029442?
This trial is sponsored by James J. Peters Veterans Affairs Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03029442's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI